Annotation of rs2631372
Allele G is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele C.
No significant association between genotype and chance of requiring an imatinib dose reduction.
From Publication
Genetic polymorphisms in ABCG2 and CYP1A2 are associated with imatinib dose reduction in patients treated for gastrointestinal stromal tumors. The pharmacogenomics journal. 2019. Verboom Michiel C et al.
Gene
Variant
Phenotype Category
Association Significance
PharmGKB ID
Score More info on scoring
Evidence for Clinical Annotations
This annotation has not been used as evidence for any clinical annotations.
Study Parameters
1.
Study type
Study size
Association p-value
Statistical analysis
Confidence interval
Allele frequency
Biogeographical group More info on groups
Population description
men; women
Study Cohort: Statistics given for multivariate analysis comparing the CC and CG genotypes against the GG genotype. P-values lower than 0.00139 were considered significant.
2.
Study type
Study size
Association p-value
Statistical analysis
Confidence interval
Allele frequency
Biogeographical group More info on groups
Population description
men; women
Study Cohort: Statistics given for multivariate analysis comparing the CC and CG genotypes. P-values lower than 0.00139 were considered significant.
3.
Study type
Study size
Association p-value
Allele frequency
Biogeographical group More info on groups
Population description
men; women
Study Cohort: P-value given for univariate analysis
Note: Alleles in PharmGKB are mapped to the positive chromosomal strand. Therefore, variants in genes on the "minus" strand (eg. VKORC1) are complemented in PharmGKB annotations.
History
No history available.